• 1
    Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999; 189: 12-19.
  • 2
    Clavel C, Masure M, Bory JP, et al. Human papillomavirus testing in primary screening for the detection of high-grade cervical lesions: a study of 7932 women. Br J Cancer. 2001; 84: 1616-1623.
  • 3
    Stoler MH, Castle PE, Solomon D, Schiffman M. The expanded use of HPV testing in gynecologic practice per ASCCP-guided management requires the use of well-validated assays. Am J Clin Pathol. 2007; 127: 335-337.
  • 4
    zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer. 2002; 2: 342-350.
  • 5
    Munger K. Disruption of oncogene/tumor suppressor networks during human carcinogenesis. Cancer Invest. 2002; 20: 71-81.
  • 6
    Riley RR, Duensing S, Brake T, Munger K, Lambert PF, Arbeit JM. Dissection of human papillomavirus E6 and E7 function in transgenic mouse models of cervical carcinogenesis. Cancer Res. 2003; 63: 4862-4871.
  • 7
    zur Hausen H. Papillomaviruses causing cancer: evasion from host-cell control in early events in carcinogenesis. J Natl Cancer Inst. 2000; 92: 690-698.
  • 8
    Castle PE, Sideri M, Jeronimo J, Solomon D, Schiffman M. Risk assessment to guide the prevention of cervical cancer. Am J Obstet Gynecol. 2007; 197: 356 e1-6.
  • 9
    Goldie SJ, Kim JJ, Myers E. Chapter 19: Cost-effectiveness of cervical cancer screening. Vaccine. 2006; 24( suppl 3): S3/164-170.
  • 10
    Solomon D, Schiffman M, Tarone R. Comparison of 3 management strategies for patients with atypical squamous cells of undetermined significance: baseline results from a randomized trial. J Natl Cancer Inst. 2001; 93: 293-299.
  • 11
    Solomon D, Schiffman M, Tarone R. ASCUS LSIL Triage Study (ALTS) conclusions reaffirmed: response to a November 2001 commentary. Obstet Gynecol. 2002; 99: 671-674.
  • 12
    Goldie SJ, Kim JJ, Wright TC. Cost-effectiveness of human papillomavirus DNA testing for cervical cancer screening in women aged 30 years or more. Obstet Gynecol. 2004; 103: 619-631.
  • 13
    Wright TC Jr, Massad LS, Dunton CJ, Spitzer M, Wilkinson EJ, Solomon D. 2006 consensus guidelines for the management of women with cervical intraepithelial neoplasia or adenocarcinoma in situ. Am J Obstet Gynecol. 2007; 197: 340-345.
  • 14
    Cuzick J, Clavel C, Petry KU, et al. Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int J Cancer. 2006; 119: 1095-1101.
  • 15
    Dillner J, Rebolj M, Birembaut P, et al. Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study. BMJ. 2008; 337: a1754.
  • 16
    Kurtycz DF, Smith M, He R, Miyazaki K, Shalkham J. Comparison of methods trial for high-risk HPV. Diagn Cytopathol. 2010; 38: 104-108.
  • 17
    Ko V, Tambouret RH, Kuebler DL, Black-Schaffer WS, Wilbur DC. Human papillomavirus testing using hybrid capture II with SurePath collection: initial evaluation and longitudinal data provide clinical validation for this method. Cancer (Cancer Cytopathol). 2006; 108: 468-474.
  • 18
    Siddiqi A, Spataro M, McIntire H, et al. Hybrid capture 2 human papillomavirus DNA testing for women with atypical squamous cells of undetermined significance papanicolaou results in SurePath and ThinPrep specimens. Cancer (Cancer Cytopathol). 2009; 117: 318-325.
  • 19
    Knoepp SM, Kuebler DL, Wilbur DC. Resolution of equivocal results with the Hybrid Capture II high-risk HPV DNA test: a cytologic/histologic review of 191 cases. Diagn Mol Pathol. 2007; 16: 125-129.
  • 20
    Tsai HT, Wu CH, Lai HL, et al. Association between quantitative high-risk human papillomavirus DNA load and cervical intraepithelial neoplasm risk. Cancer Epidemiol Biomarkers Prev. 2005; 14( 11 pt 1): 2544-2549.
  • 21
    Yuan Q, Wilbur DC. Original cervical cytology and follow-up biopsy results in positive high risk human papillomavirus DNA tests with high-level results. Acta Cytol. 2008; 52: 557-562.
  • 22
    Kuebler DL, Illingworth A, Blenc AM, Wilbur DC. A peer comparison program for the quality assurance of human papillomavirus DNA detection using the Digene Hybrid Capture II/SurePath method shows excellent analytic interlaboratory correlation. Cancer. 2007; 111: 339-343.
  • 23
    Federschneider JM, Yuan L, Brodsky J, Breslin G, Betensky RA, Crum CP. The borderline or weakly positive Hybrid Capture II HPV test: a statistical and comparative (PCR) analysis. Am J Obstet Gynecol. 2004; 191: 757-761.
  • 24
    Castle PE, Schiffman M, Scott DR, et al. Semiquantitative human papillomavirus type 16 viral load and the prospective risk of cervical precancer and cancer. Cancer Epidemiol Biomarkers Prev. 2005; 14: 1311-1314.
  • 25
    Jarboe EA, Venkat P, Hirsch MS, Cibas ES, Crum CP, Garner EO. A weakly positive HPV Hybrid Capture II result correlates with a significantly lower risk of HSIL following ASC-US cytology. Mod Pathol. 2008; 21: 207a-208a.
  • 26
    Kovacic MB, Castle PE, Herrero R, et al. Relationships of human papillomavirus type, qualitative viral load, and age with cytologic abnormality. Cancer Res. 2006; 66: 10112-10119.
  • 27
    Lorincz AT, Castle PE, Sherman ME, et al. Viral load of human papillomavirus and risk of CIN3 or cervical cancer. Lancet. 2002; 360: 228-229.
  • 28
    Sherman ME, Wang SS, Wheeler CM, et al. Determinants of human papillomavirus load among women with histological cervical intraepithelial neoplasia 3: dominant impact of surrounding low-grade lesions. Cancer Epidemiol Biomarkers Prev. 2003; 12: 1038-1044.
  • 29
    Sargent A, Bailey A, Turner A, et al. Optimal threshold for a positive hybrid capture 2 test for detection of human papillomavirus: data from the ARTISTIC trial. J Clin Microbiol. 2010; 48: 554-558.